October 24, 2014 at 22:10, a Friday night we learned that Clinuvel had gained approval for Scenesse. The share price at the time was $2.60. I had written to Wolgen thanking him for all he done for the company regardless of the outcome. He did not respond, we have not spoken since, other than a grunt at an AGM.
The share price rose 100% the next trading day only to fall back to below pre approval trading price as the arduous rollout and PV process evolved.
10 years following approval and Clinuvel are treating around 300 EPP patients in Europe, nearly all in The Netherlands and Germany.
The highlights of the last 10 years are too many to mention. Probably the HHD results stand out.
At least we still have a company up 440% in 10 years! As Rosenfeld said recently all long term investors should just piss off( or something like that)
CUV Price at posting:
$14.16 Sentiment: Sell Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)